Related Experiment Video

Updated: Jul 14, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study

Timothy S Bailey1, Howard C Zisser, Satish K Garg

  • 1North County Endocrine Medical Group, Escondido, California, USA.

Diabetes Technology & Therapeutics
|June 15, 2007
PubMed

Insights

Real-time continuous glucose monitoring (CGM) significantly lowered hemoglobin A1c (HbA1c) in adults with diabetes. Increased use of CGM devices correlated with greater HbA1c reductions, demonstrating its effectiveness in diabetes management.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Medical Devices

Background:

  • 140 adults with diabetes participated in a 12-week home-use study of real-time continuous glucose monitoring (CGM).
  • Hemoglobin A1c (HbA1c) levels were measured at baseline, week 6, and week 12 to assess glycemic control.

Purpose of the Study:

  • To evaluate the safety, tolerability, and efficacy of real-time CGM in adults with diabetes during home use.
  • To determine the impact of CGM on Hemoglobin A1c (HbA1c) levels over a 12-week period.

Main Methods:

  • Participants received CGM devices and training, with initial sensor insertion supervised by staff.
  • The CGM system provided real-time glucose values, trend graphs, and alerts at 5-minute intervals.
  • Follow-up visits every 3 weeks facilitated resupply, data download, and monitoring.

Main Results:

  • A statistically significant reduction in HbA1c of 0.4% was observed overall (P < 0.0001).
  • Significant HbA1c reductions were noted in both type 1 and type 2 diabetes subgroups, as well as those using insulin injections or pumps.
  • Subjects with baseline HbA1c >9.0% experienced the largest reduction (1.4%), and increased CGM usage correlated with greater HbA1c decrease.

Conclusions:

  • Home use of real-time CGM is safe, well-tolerated, and leads to clinically significant HbA1c reductions.
  • The study supports the utility of CGM as a valuable tool for diabetes management.
  • Further large-scale randomized controlled outcome studies are warranted to confirm CGM's long-term benefits.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...